PillRx only · Solution · Oral
Ethosuximide
Brands: Zarontin · Ethosuximide
5 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US5 NDCs
5 active makers
5 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$0.088
Latest avg · Jul 22, 2026
-7%
Since Dec 17, 2025
5
Active US suppliers
50%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
18K
Rx · 2026 Q1
8.2M
Units dispensed
-0%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it5 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Mylan Pharmaceuticals Inc. | unknown | 2 | SUPPLYING |
| Parke-Davis Div of Pfizer Inc | unknown | 1 | SUPPLYING |
| PAI Holdings, LLC dba PAI Pharma | unknown | 1 | SUPPLYING |
| Chartwell RX, LLC | unknown | 1 | SUPPLYING |
| Chartwell Governmental & Specialty RX, LLC. | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jul 29, 2021RECALLRecall (Class II): Ethosuximide Oral Solution USP 250 mg/5 mL, 16 fl oz (473 mL), Rx ONLY, Pharmaceutical Associates, Inc. Greenville, SC…
Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup. — Recalling firm: PAI Holdings, LLC. dba Pharmaceutical Associates Inc — Distributed Nationwide in the USA